Clinical trials: Antifungal Agents
Aspergillosis, Candidiasis
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
The objective of this study is to evaluate the efficacy, safety and toleration of voriconazole in the primary treatment of systemic or invasive fungal infections due to fungal pathogens for which there is no licensed therapy; and…
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001810
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Infection
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT00002742
- Testing
- amphotericin B deoxycholate, nystatin
- Where
- 59 sites in United States
- Sponsor
- Aronex Pharmaceuticals
Hematologic Diseases, Oncology Problem
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
This is a clincial validation study of a dried blood spot (DBS) method for the analysis of immunosuppressive and antifungal agents currently subject of therapeutic drug monitoring (TDM) in a pediatric population.
- Conditions
- Hematologic Diseases, Oncology Problem, Kidney Diseases, Transplantation Infection
- Trial name
- PROTECT (NCT02329808)
- Testing
- blood drawing
- Where
- Netherlands
- Volunteers
- 93 people
- Sponsor
- Radboud University Medical Center
Neutropenia
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia
The purpose of this study is to evaluate the safety and effectiveness of 2 drugs (AmBisome versus voriconazole) in treating fungal infections.
- Trial name
- NCT00008840
- Where
- United States
- Volunteers
- 866 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pediatric Acute Leukemia Induction
Antifungal Prophylaxis in Pediatric Acute Leukemia
Hypothesis:Oral Voriconazole will be as effective as intravenous Amphotericin B as antifungal prophylaxis in induction of acute leukemia (ALL, AML) in pediatric patients, with less toxicity and more convenience.
- Trial name
- NCT00624143
- Testing
- ORAL VORICONAZOLE and IV Amphotericin B
- Where
- India
- Volunteers
- 100 people
- Sponsor
- All India Institute of Medical Sciences
Tinea Pedis, Tinea Cruris
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence…
- Conditions
- Tinea Pedis, Tinea Cruris, Tinea Corporis
- Trial name
- NCT01349998
- Testing
- Product 33525
- Where
- 24 sites in United States, Belize and 3 more
- Volunteers
- 604 people
- Sponsor
- Tinea Pharmaceuticals
HIV Infections, Histoplasmosis
Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs
The purpose of this study is to determine whether stopping preventive histoplasmosis medications in patients who are currently receiving effective anti-HIV drugs will place them at risk for getting histoplasmosis again.
- Trial name
- NCT00006316
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumocystis Carinii, HIV Infections
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine
To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse…
- Trial name
- NCT00001990
- Testing
- Atovaquone
- Where
- United States
- Sponsor
- Glaxo Wellcome
Dermatophyte Infection
Fungal Resistance in Dermatophyte Infection
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment.
- Trial name
- NCT06729216
- Testing
- Antifungal susceptibility testing (AFST)
- Volunteers
- 42 people
- Sponsor
- Cairo University
Pneumonia, Pneumocystis Carinii, HIV Infections
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients.
- Trial name
- NCT00000655
- Testing
- Atovaquone, Sulfamethoxazole-Trimethoprim
- Where
- 38 sites in United States, Belgium and 6 more
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Candida Infection
Biofilm Formation and Antifungal Resistance in Candida Species
1. To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection. 2. Detection of biofilm formation by conventional and molecular methods 3.
- Trial name
- NCT07245563
- Volunteers
- 300 people
- Sponsor
- Assiut University
Stem Cell Transplantation, Graft vs Host Disease
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
Background: The gastrointestinal (GI) tract is commonly affected by acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) in patients who have undergone blood or marrow stem cell transplantation (BMT).
- Trial name
- NCT01950507
- Testing
- Budesonide, Fluconazole, Voriconazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections, Histoplasmosis
A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
- Conditions
- HIV Infections, Histoplasmosis, Blastomycosis
- Trial name
- NCT00002159
- Testing
- Itraconazole, Amphotericin B
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP
Invasive Fungal Infections
Evaluation of a Clinical Decision Support System for Fungal Infections
Invasive fungal infections are serious and frequent diseases in our hospitals, especially in intensive care units. In accordance with the institutional recommendations, it is necessary to have a clinical decision support system…
- Trial name
- NCT05656157
- Testing
- Medical device
- Where
- France
- Volunteers
- 278 people
- Sponsor
- Hospices Civils de Lyon
Infection, Invasive Fungal
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
This retrospective study is designed to provide a consistent method of screening and collecting data on patients who will serve as controls for a comparison of the efficacy of the available antifungal therapies used as salvage…
- Trial name
- NCT00230243
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Tinea Capitis
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs…
- Trial name
- NCT00117767
- Testing
- Terbinafine hydrochloride (HCl), Griseofulvin
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Novartis Pharmaceuticals
Invasive Fungal Infections
Pharmacokinetics of Fluconazole in Children (2-18 Years)
30 pediatric patients aged 2-18 years receiving fluconazole as part of standard care for the treatment or prophylaxis of an invasive fungal infection will be included in the study.
- Trial name
- FOCUS (NCT05130723)
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Otomycosis, Antifungal Agents
Nanoparticle-Based Prunus Salicina Extract vs. Clotrimazole for Otomycosis
This randomized controlled superiority trial evaluates the anti-otomycotic efficacy of Prunus salicina methanolic extract in two formulations (standard drops and chitosan nanoparticle-based drops) compared to standard 1%…
- Trial name
- NCT07867223
- Testing
- Group A, Group B, Group C
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Deraya University
Aspergillosis
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant).
- Trial name
- NCT00076869
- Testing
- MK0991, caspofungin acetate, Comparator: amphotericin B, Comparator: lipid formulation of amphotericin B and/or azole
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Pneumocystis Carinii, HIV Infections
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
To compare the efficacy and safety of dapsone versus atovaquone in preventing or delaying the onset of histologically proven or probable Pneumocystis carinii pneumonia in HIV-infected patients with CD4 counts <= 200 cells/mm3 or…
- Trial name
- NCT00000802
- Testing
- Atovaquone, Dapsone
- Where
- 44 sites in United States, Tanzania
- Volunteers
- 700 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)